Hester Biosciences Reports Strong Growth for FY26, Recommends Dividend, and Updates Key Holdings

Hester Biosciences Reports Strong Growth for FY26, Recommends Dividend, and Updates Key Holdings​

Hester Biosciences Limited announced its audited financial results for the quarter and full year ended March 31, 2026. The company's performance showcased significant growth, particularly in its Poultry Healthcare segment, while the Board of Directors also recommended a dividend and approved a key divestment of its subsidiary interest.

The company reported strong year-over-year growth across its key segments, driven by improved operational execution and product mix.

Financial Highlights (FY26)​

Hester Biosciences recorded substantial increases in both standalone and consolidated revenues and profitability for the fiscal year 2026 compared to 2025.

The consolidated financial results for the year ended March 31, 2026, showed:

• Total Revenue from Operations: INR 3,325.99 million (up 7% from INR 3,111.02 million in FY25).
• Total Income: INR 3,422.83 million.
• Profit after tax: INR 574.84 million (an increase of 99% from INR 288.26 million in FY25).
• Earnings Per Share (EPS): INR 67.57 (not annualised, up 99% from INR 33.89 in FY25).

The quarterly results for the period ended March 31, 2026, reported:

Standalone Performance​

Standalone results reflected impressive growth:

• Total Income: INR 2,997.71 million (up 2% from INR 2,912.30 million in FY25).
• Profit after tax: INR 521.00 million (up 64% from INR 318.42 million in FY25).
• EPS (not annualised): INR 61.24 (up 64% from INR 37.43 in FY25).

The company noted that the EBITDA and Profit After Tax (PAT) growth were primarily driven by a stronger contribution from the Poultry Healthcare Division, coupled with improved product mix and cost optimization efforts.

Segment Revenue and Results​

The Poultry Healthcare and Animal Healthcare divisions continue to be the primary revenue drivers.

In the standalone segment results, the Poultry Healthcare Division recorded a total revenue of INR 2,060.79 million for FY26, showing robust growth. The Animal Healthcare Division's total revenue reached INR 818.32 million for the fiscal year.

Corporate Governance and Operational Updates​

The Board of Directors confirmed several strategic and corporate updates:

• Dividend Recommendation: The Board recommended a dividend of INR 11 (Eleven) per equity share, representing 110% for the financial year 2025-26, pending approval by the shareholders at the ensuing Annual General Meeting.
• Director Appointment: Ms. Priya Gandhi was re-appointed as the Executive Director of the Company for a term of three years, effective from October 28, 2026.
• Divestment: The Board approved the sale of a significant stake in its subsidiary, Texas Lifescience Private Limited (TLPL). The Company will divest 43.81% equity shareholding out of its 54.81% stake in TLPL by transferring 2,163,377 Equity Shares of INR 10 each at a price of INR 42.34 per share. TLPL ceased to be a subsidiary of the company from March 27, 2026.

Operationally, the Company also highlighted the capitalization of its BSL 3 facility as part of ongoing capacity expansion and infrastructure strengthening initiatives during the quarter.

***

Note: The provided tables and detailed financial statements contain specific data points regarding revenues, expenses, and assets, which demonstrate the comprehensive financial health of the Group. The full financial statements and the press release are available to stakeholders.

HESTERBIO Stock Price Movement​

Shares of Hester Biosciences Limited are surging in live trading, rallying 12.63% as of 12:25 PM, currently trading at ₹1960. The company is seeing robust institutional interest, evidenced by a volume of 103,337 shares, and holding a strong gap above its day's low of ₹1732.9.